Logo

VTVT

vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc. • NASDAQ
$26.51 ▼ -1.81% (-0.49)
Market Cap $69.38 M
52w High $33.16
52w Low $13.15
Dividend Yield 0%
P/E -8.03
Volume 186
Outstanding Shares 2.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $10.699M ▲ $-8.698M ▼ 0% $-1.08 ▼ $-10.338M ▼
Q2-2025 $0 $7.721M ▲ $-6.046M ▼ 0% $-0.92 ▼ $-7.718M ▼
Q1-2025 $0 ▼ $6.503M ▲ $-5.092M ▼ 0% ▲ $-0.77 ▼ $-6.494M ▼
Q4-2024 $17K ▲ $4.887M ▼ $-3.634M ▲ -21.376K% ▼ $-0.63 ▲ $-4.415M ▲
Q3-2024 $0 $6.506M $-4.783M 0% $-0.88 $-5.818M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $98.504M ▲ $99.494M ▲ $28.951M ▲ $70.543M ▲
Q2-2025 $25.922M ▼ $26.448M ▼ $24.043M ▲ $2.762M ▼
Q1-2025 $31.059M ▼ $32.027M ▼ $23.13M ▼ $7.92M ▼
Q4-2024 $36.746M ▼ $38.266M ▼ $23.965M ▼ $12.199M ▼
Q3-2024 $41.571M $43.164M $25.251M $15.008M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.698M ▼ $-5.222M ▼ $0 $77.804M ▲ $72.582M ▲ $-5.222M ▼
Q2-2025 $-7.38M ▼ $-5.095M ▲ $0 $-42K ▼ $-5.137M ▲ $-5.095M ▲
Q1-2025 $-6.217M ▼ $-5.687M ▼ $0 $0 $-5.687M ▼ $-5.687M ▼
Q4-2024 $-3.634M ▲ $-4.825M ▲ $0 $0 ▼ $-4.825M ▼ $-4.825M ▲
Q3-2024 $-5.84M $-6.418M $0 $2.463M $-3.955M $-6.418M

Five-Year Company Overview

Income Statement

Income Statement vTv is still a pure research-stage company: it has essentially no product revenue over the past several years and runs a predictable operating loss each year. The losses are modest in absolute size but very large relative to its tiny revenue base, which is typical for a small biotech funding clinical trials. Earnings per share look very volatile and deeply negative mainly because of the reverse stock split rather than a sudden business collapse. Overall, the income statement shows a business fully in “investment mode” with costs driven by development rather than by commercial operations.

Balance Sheet

Balance Sheet The balance sheet is very small and simple. Assets are almost entirely cash, with little in the way of physical or long‑term assets, which fits a lean, R&D‑focused biotech. The company carries no financial debt, which reduces interest burden but also means it relies heavily on equity funding. Shareholders’ equity was negative for several years and only recently turned slightly positive, signaling that accumulated losses have largely consumed past capital. The later private placement mentioned in the narrative suggests a stronger cash position after 2024, but the business remains highly dependent on continued access to financing.

Cash Flow

Cash Flow Cash flow reflects a straightforward story: regular cash outflow from operations to fund clinical work, with no meaningful cash inflows from sales. Free cash flow is negative and closely tracks operating cash usage because capital spending is minimal. The burn rate looks relatively steady year to year, which can help planning but also underlines that the company must periodically raise new capital to continue trials. Until there is a commercial product or substantial partnering income, internal cash generation is not a source of support for the business.

Competitive Edge

Competitive Edge Competitively, vTv is trying to carve out a focused niche rather than compete broadly across diabetes and immunology. Its lead program, cadisegliatin, targets an unmet need as an oral add‑on therapy for type 1 diabetes, an area where there are currently no approved oral adjuncts. The Breakthrough Therapy designation and long‑dated patents described in the materials provide meaningful regulatory and intellectual‑property support, forming a potential moat if the drug succeeds. However, the company is small and faces powerful incumbents in diabetes and dermatology, so commercialization would likely require strong partnerships or significant scaling. The overall competitive position is promising but very much contingent on clinical success and regulatory outcomes.

Innovation and R&D

Innovation and R&D Innovation is the company’s core asset. Cadisegliatin, a liver‑selective glucokinase activator, is designed to improve blood sugar control while reducing dangerous low‑sugar episodes, which would be a meaningful clinical advance if confirmed in Phase 3. The drug also benefits from new patent protection into the 2040s and a resumed late‑stage trial after a temporary clinical hold, according to the provided narrative. HPP737, its PDE4 inhibitor for psoriasis and other inflammatory conditions, adds a second, partnered shot on goal and is intended to offer better tolerability than existing drugs. Beyond these, vTv appears to have earlier‑stage compounds but with less visibility. Overall, R&D is highly concentrated in a small number of programs, which amplifies both the potential upside and the scientific and regulatory risk tied to each major trial readout.

Summary

vTv Therapeutics is a classic early‑stage biotech: no commercial products, small but persistent operating losses, and a balance sheet built mainly from equity financing rather than earnings. The company’s value proposition centers almost entirely on its lead diabetes candidate, backed by differentiated science, regulatory support, and long patent life, plus a partnered inflammatory program that could provide additional upside. Financially, the business is lean, cash‑burning, and reliant on capital markets and partnerships to fund its pipeline through late‑stage trials. The overall profile is high‑risk and outcome‑dependent, with future prospects hinging on clinical data, regulatory decisions, and the ability to translate scientific promise into a sustainable commercial position.

NEWS

November 6, 2025 · 4:15 PM UTC

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

October 9, 2025 · 8:00 AM UTC

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Read more

September 3, 2025 · 4:57 PM UTC

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Read more

September 3, 2025 · 8:00 AM UTC

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Read more

September 2, 2025 · 8:00 AM UTC

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Read more